title: Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.
abstract: The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating alpha-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both alpha-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of alpha-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.
authors.affiliation: Department of Urology, New York University School of Medicine New York, NY.
authors.forename: Herbert
authors.initials: H
authors.lastname: Lepor